Drug recall · September 1, 2021
Micafungin for Injection recall
Why: Labeling; Incorrect or Missing Package Insert: The package insert provided with the product does not include all required sections approved for this product. This includes aspects of Adverse Reactions, Drug Interactions and Use in Specific Populations.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Micafungin for Injection, 100 mg/vial, Single-Dose Vial, Sterile, Rx Only, For Intravenous Infusion Only, Manufactured for: Xellia Pharmaceuticals USA, LLC, Buffalo Grove, IL 60089. NDC 70594-037-01
- Lots / codes
Lot 467111, exp 1/2023
- Quantity
- 9,161 (50mg and 100 mg vials total)
- Company
- Xellia Pharmaceuticals USA, LLC, Buffalo Grove, IL
- Distribution
- Nationwide USA
- Initiated
- August 6, 2021 · Voluntary: Firm initiated
- Classified
- August 20, 2021
- Reported
- September 1, 2021
- Ended
- September 29, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Micafungin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.